The China Alzheimer’s disease diagnostics market was valued at USD 319.6 million in 2024 and is projected to reach USD 617.8 million by 2030, growing at a CAGR of 11.7% from 2025 to 2030. The rapid market expansion is primarily driven by the increasing prevalence of Alzheimer’s disease (AD), rising adoption of personalized diagnostic products, growing utilization of biomarkers in disease detection, and continuous technological advancements in medical imaging. Furthermore, increasing government investments and research and development (R&D) efforts are playing a crucial role in accelerating market growth.

One of the major contributing factors to the market’s expansion is China’s rapidly aging population. With over 280 million individuals aged 60 and above, the country is facing a sharp rise in age-related disorders such as Alzheimer’s disease. This demographic shift is creating a heightened need for early diagnostic and intervention tools. In response, the Chinese government has made dementia screening a national health priority. Public hospitals are strengthening diagnostic infrastructure, while domestic biotechnology companies are investing heavily in R&D focused on biomarker testing. Collaborations with global firms are also facilitating access to advanced imaging systems and blood-based diagnostic technologies, contributing to a more robust Alzheimer’s disease diagnostics ecosystem in China.

The market is further defined by a strong wave of innovation, particularly in biomarker and neuroimaging technologies. These advancements enable earlier, more precise diagnosis, improving treatment outcomes and allowing for personalized care. A notable example includes China’s National Medical Products Administration (NMPA) approval of AriBio’s IND application in May 2024 for a Phase III clinical trial of AR1001 for early Alzheimer’s disease. The Polaris-AD trial, set to take place across 20 sites in China, is designed as a double-blind, placebo-controlled study to evaluate the oral PDE5 inhibitor’s safety and efficacy using parameters such as the Geriatric Depression Scale (GDS), Mini-Mental State Examination (MMSE), and various biomarkers.

Key Market Trends & Insights:

• By Diagnostic Technique: The imaging techniques segment dominated the market with the largest share of 41.2% in 2024, driven by the extensive use of MRI, PET, and CT scans in clinical diagnosis. The biomarkers segment is expected to record the highest CAGR over the forecast period, supported by the growing preference for non-invasive and highly accurate diagnostic tools to monitor disease progression.
• By Type: The diagnosis segment held the largest market share in 2024 and is anticipated to grow at the fastest CAGR during the forecast period, owing to increasing adoption of early diagnostic tools and advanced imaging technologies. The screening segment is projected to register a significant CAGR over the forecast period, as awareness about early detection of Alzheimer’s continues to increase.
• By End-Use: The academic research and institutes segment dominated the market in 2024, accounting for the largest share, and is expected to grow at the fastest CAGR, driven by expanding research activities and clinical studies. The hospitals segment also accounted for a notable market share and is projected to register strong growth due to the rising adoption of advanced diagnostic technologies and government initiatives to improve healthcare infrastructure.

Order a free sample PDF of the China Alzheimer’s Disease Diagnostics Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insights:

The China Alzheimer’s disease diagnostics market is moderately fragmented, with several global and domestic players contributing to competition and innovation. Leading companies include Fujirebio, ALZpath, Quanterix, Hoffmann-La Roche, and others. These firms are focusing on strategies such as geographic expansion, new product launches, strategic collaborations, and mergers and acquisitions to strengthen their market presence. Fujirebio is known for its innovative biomarker assays targeting neurodegenerative, oncological, and infectious diseases. Through its subsidiary, Fujirebio China Co., Ltd., the company is expanding access to advanced diagnostic solutions using its fully automated LUMIPULSE platform. Quanterix, a U.S.-based diagnostics company, is recognized for its highly sensitive Simoa (single-molecule array) technology, which allows for early detection of biomarkers at femtomolar levels. The company’s recent partnership with UltraDx, a Shanghai-based diagnostics firm, marks a strategic expansion into the Chinese market, enhancing access to state-of-the-art Alzheimer’s diagnostic technologies.

Overall, the China Alzheimer’s disease diagnostics market is entering a transformative phase characterized by technological advancement, government support, and growing collaboration between domestic and international players. These factors are collectively driving innovation and accessibility, strengthening the country’s capacity to combat Alzheimer’s disease through early and accurate diagnosis.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the China Alzheimer’s disease diagnostics market is experiencing strong growth, driven by the country’s aging population, increasing awareness of early detection, and advancements in diagnostic technologies such as biomarkers and neuroimaging. Government initiatives and expanding R&D investments are playing a crucial role in strengthening diagnostic infrastructure and promoting innovation. Collaborations between domestic and international companies are further enhancing access to advanced testing solutions, fostering a competitive and technology-driven market environment. The growing emphasis on early and accurate diagnosis is expected to improve patient outcomes and shape the future of Alzheimer’s care in China. Overall, the market is poised for sustained expansion as healthcare systems continue to prioritize dementia diagnosis and prevention.